Hillevax Inc (HLVX) - Total Assets
Based on the latest financial reports, Hillevax Inc (HLVX) holds total assets worth $174.91 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore HLVX operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Hillevax Inc - Total Assets Trend (2019–2024)
This chart illustrates how Hillevax Inc's total assets have evolved over time, based on quarterly financial data. See Hillevax Inc net assets for net asset value and shareholders' equity analysis.
Hillevax Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Hillevax Inc's total assets of $174.91 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 80.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Hillevax Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HLVX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hillevax Inc's current assets represent 92.6% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 80.2% of total assets in 2024, down from 89.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Hillevax Inc Competitors by Total Assets
Key competitors of Hillevax Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.40 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
China | CN¥3.22 Billion |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥3.65 Billion |
Hillevax Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.39 | 5.14 | 0.15 |
| Quick Ratio | 26.39 | 5.14 | 0.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $156.09 Million | $203.36 Million | $-2.77 Million |
Hillevax Inc - Advanced Valuation Insights
This section examines the relationship between Hillevax Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.54 |
| Asset Growth Rate (YoY) | -44.1% |
| Total Assets | $192.69 Million |
| Market Capitalization | $104.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hillevax Inc's assets below their book value (0.54x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hillevax Inc's assets decreased by 44.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hillevax Inc (2019–2024)
The table below shows the annual total assets of Hillevax Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $192.69 Million | -44.06% |
| 2023-12-31 | $344.43 Million | +8.58% |
| 2022-12-31 | $317.21 Million | +149.46% |
| 2021-12-31 | $127.16 Million | +25080.00% |
| 2020-12-31 | $505.00K | +11.97% |
| 2019-12-31 | $451.00K | -- |
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical prod… Read more